Navigation Links
ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy
Date:2/28/2011

patients who reported two or more flares by 66% (p<0.0001).

Detailed data from both the PRE-SURGE 2 and RE-SURGE studies will be presented at future scientific conferences.  The safety and efficacy of ARCALYST in the gout setting have not been evaluated by the U.S. Food and Drug Administration.  ARCALYST is not approved for use in gout.

About the PRE-SURGE 2 StudyThe Global PRE-SURGE 2 (PREventative Study against URate-lowering drug-induced Gout Exacerbations) study was a double-blind, placebo-controlled study which evaluated the number of gout flares per patient over the first 16 weeks following initiation of allopurinol therapy.  The trial was conducted in South Africa, Germany, and parts of Asia. In the trial, a gout flare was defined as patient-reported acute articular pain typical of a gout attack that was deemed (by the patient and/or the investigator) to require treatment with an anti-inflammatory therapeutic and involved at least three of four signs/symptoms (joint swelling, redness, tenderness, and pain) and one or more of the following: rapid onset of pain, decreased range of motion, joint warmth, or other symptoms similar to a prior gout flare.  A total of 248 patients were randomized on a 1:1:1 basis to receive one of the following treatment regimens:

  • ARCALYST 160 mg as an initial subcutaneous loading dose, followed by weekly 80 mg subcutaneous injections for a total of 16 weeks
  • ARCALYST 320 mg as an initial subcutaneous loading dose, followed by weekly 160 mg subcutaneous injections for a total of 16 weeks
  • Subcutaneous weekly placebo injections for 16 weeks

  • Primary and key secondary endpoint results were as follows:PlaceboARCALYST® (rilonacept) 80 mgARCALYST® (rilonacept) 160 mg n82

    82

    84*Primary endpointMean # of flares per patient (% reduction compared to placebo)1.23

    0.35

    (72% reduction)


    '/>"/>

    SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline
    2. New IonWorks Barracuda Automated Patch Clamp System Meets Need for Affordable, Accelerated Screening of Ligand- & Voltage-Gated Ion Channels Via Direct Electrophysiology Assays
    3. US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow
    4. LEO Pharmas PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
    5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
    6. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
    7. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
    8. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
    9. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
    10. MADIT-CRT Trial Meets Primary Endpoint
    11. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)... July 24, 2014  In any given hospital in ... patients has at least one hospital-acquired infection, according to ... many of these infections prove fatal. And as increased ... number of patient deaths per year, infection control efforts ... Consequently, a stronger emphasis is being placed ...
    (Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- Delivery of ... order is placed. Photo - ... professional and in-depth market survey on Global and ... the basic information of Hemodialysis Machine including its ... explores global and China,s top manufacturers of Hemodialysis ...
    (Date:7/24/2014)... -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) today ... 2014. Three Months Ended 06/30/14Three Months Ended 06/30/13 ,  Percentage ... 51% Non-GAAP Net Sales , $278.8 Million , $196.1 ... , $1.12 , 37% Non-GAAP Diluted ... 37%  Six Months Ended 06/30/14Six Months Ended 06/30/13 , ...
    Breaking Medicine Technology:Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Questcor Reports Record Second Quarter Financial Results 2Questcor Reports Record Second Quarter Financial Results 3Questcor Reports Record Second Quarter Financial Results 4Questcor Reports Record Second Quarter Financial Results 5Questcor Reports Record Second Quarter Financial Results 6Questcor Reports Record Second Quarter Financial Results 7Questcor Reports Record Second Quarter Financial Results 8Questcor Reports Record Second Quarter Financial Results 9Questcor Reports Record Second Quarter Financial Results 10Questcor Reports Record Second Quarter Financial Results 11Questcor Reports Record Second Quarter Financial Results 12Questcor Reports Record Second Quarter Financial Results 13Questcor Reports Record Second Quarter Financial Results 14Questcor Reports Record Second Quarter Financial Results 15Questcor Reports Record Second Quarter Financial Results 16Questcor Reports Record Second Quarter Financial Results 17Questcor Reports Record Second Quarter Financial Results 18Questcor Reports Record Second Quarter Financial Results 19Questcor Reports Record Second Quarter Financial Results 20Questcor Reports Record Second Quarter Financial Results 21Questcor Reports Record Second Quarter Financial Results 22Questcor Reports Record Second Quarter Financial Results 23Questcor Reports Record Second Quarter Financial Results 24Questcor Reports Record Second Quarter Financial Results 25Questcor Reports Record Second Quarter Financial Results 26Questcor Reports Record Second Quarter Financial Results 27Questcor Reports Record Second Quarter Financial Results 28
    ... PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, announced today that the Company,s ... the position of President and Chief Executive Officer, effective ... Chief Executive Officer in May 2010, and prior thereto ...
    ... Inc., today reported positive clinical trial results on ... inhalation), an antibiotic that is entering Phase III ...  The results demonstrate significant clinical benefit and complete ... of lung infections due to the bacterium, ...
    Cached Medicine Technology:PharmAthene Appoints Eric I. Richman President and Chief Executive Officer 2PharmAthene Appoints Eric I. Richman President and Chief Executive Officer 3ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients 2ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients 3ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients 4ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients 5
    (Date:7/24/2014)... rare procedure occasionally performed during Jewish circumcisions that involves ... herpes simplex virus type 1 (HSV-1) transmissions documented in ... conducted by Penn Medicine researchers and published online ... Society found. The reviewers, from Penn,s ... in New York, Canada and Israel. , The practiceknown ...
    (Date:7/24/2014)... (Boston)--Minority women who received the Human Papillomavirus Vaccination ... rates of abnormal Pap test results than those ... the journal Sexually Transmitted Diseases . ... Health and School of Medicine conducted a cross-sectional ... undergoing routine cervical cytology testing. HPV status and ...
    (Date:7/24/2014)... According to market research report ... Roadmap, Forecasts and Analysis - 2018", the 3D ... reach $7.7 billion by 2018 at a CAGR ... market data tables and 30 figures spread through ... Market: Global Advancements, Business Models, Technology Roadmap, Forecasts ...
    (Date:7/24/2014)... New York (PRWEB) July 24, 2014 ... lawsuit ( http://www.drugbot.com/testosterone/lawsuit/ ) against the manufacturer of ... the risks associated with the low testosterone injection, ... which was filed in the Ontario Superior Court ... that use of low testosterone therapy is associated ...
    (Date:7/24/2014)... -- Giving low-income families vouchers to buy fruits and ... these healthy foods, according to a new study. ... In addition to not having adequate access to healthy ... could help address both of these obstacles, the researchers ... market incentives may be able to bring a low-income ...
    Breaking Medicine News(10 mins):Health News:Link between ritual circumcision procedure and herpes infection in infants examined 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 3Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 4Health News:Testosterone Lawsuit News: Canadian Plaintiffs File Class Action Lawsuit Against Manufacturer of Delatestryl Testosterone Injection, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuit News: Canadian Plaintiffs File Class Action Lawsuit Against Manufacturer of Delatestryl Testosterone Injection, Bernstein Liebhard LLP Reports 3Health News:Farmers' Market Vouchers May Help Poorer Families Eat Healthier 2
    ... 3 The National,Fibromyalgia Association today announced that ... III, will be its designated spokeswoman to,help raise ... illness that experts believe affects up to 10 ... Mrs. Bremer was diagnosed with fibromyalgia 25 ...
    ... join Terrence Howard, Natalie, Maines and Abigail Breslin to ... ... SAN FRANCISCO, Oct. 3 Gap is proud to,introduce ... to help eliminate AIDS in Africa. Captured by acclaimed,photographer Annie ...
    ... /PRNewswire-FirstCall/ - Predictive medicine company,PreMD Inc. (TSX: PMD; ... on the,company,s 510(k) application to the US Food ... On Wednesday, October 3, 2007, Dr. Brent ... present at BioContact Quebec, a leading,annual biopharmaceutical conference. ...
    ... New research from the Howard Florey Institute in Melbourne ... cause epilepsy in infants. , Infants are more susceptible ... rapid rate, making their brain cells excitable. Their neurons ... cells, which can disrupt normal brain activity and results ...
    ... Laboratory (EMBL), the University of Helsinki, Finland, the ... officially launch their new Nordic EMBL Partnership for ... and collaborations between the partners and will facilitate ... for an initial period of five years. ...
    ... spur these outbursts , WEDNESDAY, Oct. 3 (HealthDay News) ... problems can help prompt dogs to bite children, a ... Pennsylvania looked at 111 cases involving 103 dogs that ... clinic over four years. , "Guarding of resources and ...
    Cached Medicine News:Health News:Frances Winfield Bremer, Wife of Ambassador L. Paul Bremer, III, to Become Spokeswoman for the National Fibromyalgia Association 2Health News:Gap Introduces Inspirational Marketing Campaign to Celebrate First Anniversary of Global Launch of Gap (PRODUCT) RED 2Health News:Gap Introduces Inspirational Marketing Campaign to Celebrate First Anniversary of Global Launch of Gap (PRODUCT) RED 3Health News:Gap Introduces Inspirational Marketing Campaign to Celebrate First Anniversary of Global Launch of Gap (PRODUCT) RED 4Health News:PreMD Inc. Provides Corporate Update 2Health News:PreMD Inc. Provides Corporate Update 3Health News:Research shows how genetic mutation causes epilepsy in infants 2Health News:EMBL reaches north 2Health News:Medical, Behavioral Woes Can Drive Dogs to Bite 2
    ... for strength and durability. Four 64 mirrors ... minimal lens rotation. Choice of three handles ... Small diameter contact surface allows static or ... polymer coating protects mirrors and is compatible ...
    ... Three mirrors of 64, 67 ... diameter contact surface for use ... be viewed through the central ... polymer coating protects mirrors and ...
    Small size gonio lens with one 62 mirror. Compact knurled ring simplifies 360 viewing of the anterior chamber angle....
    Lacrimal cannula blunt tip with 0.3 mm side port, straight....
    Medicine Products: